Ingalls & Snyder LLC’s United Therapeutics UTHR Stock Holding History

Ingalls & Snyder LLC’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-431	Closed	-$256K	–	498
2026 Q1	$256K	Sell	431 -9	-2%	-$4.48K	0.01%	390
2025 Q4	$214K	Buy	+440	New	+$205K	0.01%	433

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Ingalls & Snyder LLC's UTHR Position: Q2 2026 in Review

Ingalls & Snyder LLC sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 431 shares — an estimated $256K sold.

Ingalls & Snyder LLC first reported a position in UTHR in Q4 2025 and held it in 2 quarters. The position peaked at $256K in Q1 2026. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Ingalls & Snyder LLC reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
Ingalls & Snyder LLC sold 431 United Therapeutics shares in Q2 2026, an estimated $256K.
Ingalls & Snyder LLC first reported a position in United Therapeutics in Q4 2025 and held it in 2 quarters.
Ingalls & Snyder LLC's United Therapeutics position peaked at $256K in Q1 2026.
878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Ingalls & Snyder LLC's 13F filing for Q2 2026, filed 14 Aug 2026.